Abbott Laboratories (ABT)
NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
119.27-5.26 (-4.22%)
As of 12:36PM EDT. Market open.
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 124.53 |
| Open | 120.50 |
| Bid | 119.81 x 2200 |
| Ask | 119.90 x 800 |
| Day's Range | 119.02 - 122.00 |
| 52 Week Range | 86.16 - 128.54 |
| Volume | 5,899,372 |
| Avg. Volume | 5,203,862 |
| Market Cap | 211.29B |
| Beta (5Y Monthly) | 0.70 |
| PE Ratio (TTM) | 47.65 |
| EPS (TTM) | 2.50 |
| Earnings Date | Apr 20, 2021 |
| Forward Dividend & Yield | 1.80 (1.45%) |
| Ex-Dividend Date | Apr 14, 2021 |
| 1y Target Est | 134.95 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
19% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
View moreRelated Research
- Motley Fool
Abbott's Sales Soared in Q1, but Not Enough to Satisfy Wall Street
Abbott Laboratories (NYSE: ABT) entered 2020 as a strong and growing business. For the quarter, Abbott Labs reported revenue of $10.5 billion, a 35% year-over-year jump. In the prior-year period, Abbott posted GAAP earnings of $564 million, or $0.31 per share.
- Investor's Business Daily
What Abbott's 'Rare, Off-Color' Earnings Say About The Covid Testing Scene
Abbott Laboratories posted a "rare, off-color" first-quarter earnings report, an analyst said Tuesday as total and Covid-related sales came in light. In response, ABT stock fell.
- Zacks
Abbott (ABT) Q1 Earnings Miss, Diagnostic Test Sales Solid
Abbott (ABT) reports strong Diagnostics sales for the first quarter driven by growing demand for its BinaxNOW, Panbio and ID NOW rapid testing platforms.
© 2021 Verizon Media. All rights reserved.
